External Collaborative Research
The External Collaborative Research (ECR) program is open to all qualified academic and community-based scientists or consortia that are interested in proposing a study and wish to collaborate with Boehringer Ingelheim to develop a protocol and analyze and publish the results.
In addition to providing intellectual contributions, Boehringer Ingelheim may provide drug and/or financial support for an ECR. Boehringer Ingelheim does not serve as the Regulatory Sponsor for an ECR.
The preliminary budget for ECRs should reflect fair market value for all costs and cannot include direct salary support for the Principal Investigator. Budgets for ECRs will be further negotiated pending finalization of the collaborative protocol.
While the research interests listed within the therapeutic areas are of focus to Boehringer Ingelheim, other research interests may be considered.
Apply for Funding
Visit our Grants and Funding Portal
to submit a new application now.
- Explore the effects of empagliflozin on diseases of the cardio-renal-metabolic systems in patients in under-represented populations
- Understand the extent of real-world implementation of guideline-based management of patients and/or solutions to overcome barriers of GDMT implementation
- Examine the role of empagliflozin in transition-of-care models to outpatient setting in patients with cardio-renal[1]metabolism diseases
- Examine the role of empagliflozin in collaborative care models of disease of the cardio-renal-metabolic systems
- Establishing sequential and interconnected disease pathway to support the impact of early treatment on CRM pathway
- Understand the duration of GDMT for CRM conditions and factors associated with treatment discontinuation & re-initiation
- Studies investigating the natural course of the disease in patients with GPP (including risk factors; predictors, triggers, frequency and impact of flares; symptoms between flares; systemic symptoms; mortality)
- Studies investigating frequency and impact of extracutaneous manifestations and comorbidities (Anxiety/Depression, Cardiovascular Disease) in patients with GPP
- Studies to support the development, evaluation and/or validation of tools that assess patient-reported outcomes in patients with GPP
- Studies investigating the limitations (residual symptoms, incomplete/delayed flare resolution etc) of therapies based on other MOAs used to treat GPP
- Studies investigating pathogenesis of GPP
- Studies investigating incidence and/or prevalence of GPP
- Studies investigating management of patients with GPP, including treatment patterns, supportive and/or interventions to support/increase adherence to treatments (e.g., home programs, nurse support, other innovative digital tools)
Schizophrenia
- Evaluate patient assessment, symptom evaluation, and diagnosis patterns for negative symptoms
- Evaluate patient assessment, symptom evaluation, and diagnosis patterns for cognitive symptoms
- Assess the treatment landscape and trajectory of disease progression for cognitive and negative symptoms
Post-Traumatic Stress Disorder
- Evaluate patient assessment, symptom evaluation, and diagnosis patterns
- Assess the treatment landscape and trajectory of disease progression
- Evaluate disease progression with respect to index event
Digital Therapeutics
- Increase the clinician's awareness of the current unmet medical needs and burden of disease in patients with schizophrenia, including cognitive and negative symptoms associated with schizophrenia as well as the potential utility of digital therapeutics in psychiatry, including schizophrenia.
- Improve the clinician's understanding of the management and limitations of treating cognitive and negative symptoms of schizophrenia, as well as ongoing developments in clinical research in schizophrenia and digital therapeutics in psychiatry.
Major Depressive Disorder
- Evaluate patient assessment, symptom evaluation, and diagnosis patterns
- Assess the treatment landscape and trajectory of disease progression
- Understand the gaps in the progression and clinical management of MASH and advanced liver disease
Funding Only (non-drug) requests
- Understanding the physical and psychological burden of disease for patients living with Obesity
- Understanding weight stigma and obesity bias and its impact on the clinical management of Obesity
- Understanding QOL data available and additional opportunities to characterize positive impact of pharmacologic treatments (non-scale victories)
- Understanding physicians’ recognition in the difference in morbidity and mortality between patients with high waist to hip ratio (visceral fat) vs. other distribution (use of clinical tools/measurement in current practice, evaluation of current practices)
- Understanding patient factors in patient’s acceptance of treatment and factors encouraging/supporting adherence (to treatment and management)
Soft Tissue Sarcoma
- Real World Data: The natural history, development and progression of the disease, molecular testing and pathological subtyping, diagnostic/treatment landscape and efficacy/safety outcomes
- Monotherapy or combination therapy (including novel treatment combinations or radiotherapy) in MDM2 amplified or overexpressed tumors (p53 wild type)
Biliary Tract Cancer
- Real World Data: The natural history, development and progression of the disease, molecular testing and pathological subtyping, diagnostic/treatment landscape and efficacy/safety outcomes
- Combination therapy (including novel treatment combinations) in MDM2 amplified or overexpressed tumors (p53 wild type)
Non-Small Cell Lung Cancer
- Real World Data: The natural history, development and progression of the disease, molecular testing and pathological subtyping, diagnostic/treatment landscape and efficacy/safety outcomes
- Monotherapy or combination therapy (including novel treatment combinations) in NSCLC with a documented HER2 aberration: TKD and non-TKD mutation positive OR overexpression OR gene amplification OR gene rearrangement involving HER2
Fibrosing ILD
- Studies investigating newer tools for ILD screening, earlier diagnosis, or disease assessment
- Studies investigating the natural course of the disease in patients (pediatric and adult) with ILDs (including risk factors and predictors of disease progression)
- Studies investigating management of ILDs (in pediatric and adult patients) including:
- Diagnosing and managing co-morbidities
- Diagnosing and managing acute exacerbations
- Evaluating and managing extra-pulmonary manifestations of patients (pediatric and adult) with autoimmune-ILDs
- Non-pharmacologic management, including supportive and palliative care, home monitoring programs, nurse support, rehabilitation, physical training, oxygen use, and other innovative digital tools
Proposals in the following areas are not being considered:
Biosimilars, Fibrosing ILDs
FAQs
Yes. Boehringer Ingelheim requires applications to be submitted online via our Grants and Funding portal. Applications received through other means will not be considered.
Yes. You may apply on behalf of the Sponsor-Investigator, providing the Sponsor-Investigator’s information within the application as requested.
In general, grant funding to support clinical (interventional and non-interventional) and health outcomes research studies are all acceptable proposals. Requests for Proposals (RFPs) may include more specificity.
Required documents include a fully executed contract between Boehringer Ingelheim and the investigator’s institution, regulatory documents (IND or exemption), and copy of institutional review board (IRB) or Institutional Animal Care and Use Committee (IACUC) approval.
No, you do not need to complete the entire application in one session. You are able to save your work by clicking “Save Draft.” You can make changes to the application prior to submitting. However, once you submit your application, it will be locked from editing.
- Please submit a detailed Excel budget sheet.
- Budgets must be developed based on activities, services and consumable supplies directly related to the project. Direct support for Principal Investigator salary will not be accepted. Cost effectiveness of the project will be considered in the overall evaluation. If your application is approved, as part of the fair market value assessment, applicants may be asked to provide written justification for facilities and administrative costs.
- Overhead rate – BI will support a maximum overhead rate of 50%.
- This 50% cap is intended to provide greater funding to support proposed research activities.
- The overhead rate is only applicable to total direct study costs and will not be paid on indirect study costs.
- If your institution’s overhead rate exceeds 40%, BI will require a copy of the exemption letter.
